Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Vaccine Technology 2009 Conference

Veterinary Diagnostics Markets

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

Royalty Financing Agreements in Pharma, Biotech and Diagnostics

New Products

Attention Deficit Hyperactivity Disorder: Diagnosis and Treatment

Bioinformatics Market Potential

Biotechnology in the European Union; Trends, Investing & Country Profiles

China Pharmaceutical Industry: Analysis and Market Trends

European Generic Drug Market Potential

Global Biotechnology Markets Trends

Strategic Alliances in World Pharma and Biotech Markets

Understanding China's Chemical Industry

Understanding Genomics and Global Health Impacts

Understanding Pharmacogenomics

BioPortfolio | Datamonitor Healthcare Reports | Stakeholder Insight: Spondyloarthropathies - Disease perception limits market potential

Stakeholder Insight: Spondyloarthropathies - Disease perception limits market potential

Psoriatic arthritis and ankylosing spondylitis form part of the group of diseases known as the spondyloarthropathies. Psoriatic arthritis is a form of inflammatory arthritis associated with psoriasis, whilst ankylosing spondylitis causes arthritis of the spine and sacroiliac joints. Moderate-severe disease for both patient groups is frequently treated with similar therapies, including biologics.

Scope

*Analysis of the results of a survey of 180 rheumatologists and 180 dermatologists supported by key opinion leader interviews

*Overview of epidemiology and patient segmentation in psoriatic arthritis and ankylosing spondylitis

*Detailed presentation and referral information including the involvement of various physician specialties from symptom onset to therapy management

*Treatment trees for each of the seven major markets in both psoriatic arthritis and ankylosing spondylitis

Highlights

Physician education is a major unmet need in both psoriatic arthritis and ankylosing spondylitis, with the targeting of primary care physicians identified as a crucial for improving low diagnosis rates. Physicians surveyed estimate low diagnosis rates, 50% in psoriatic arthritis and 60% ankylosing spondylitis.

Systemic immunosuppressants are useful across all psoriatic arthritis severities, however the safety of long term methotrexate use is questioned in psoriatic arthritis patients, who are vulnerable to liver damage, creating an opportunity for biologics. Fear of disfigurement by psoriasis drives continued use of topical therapies and high compliance.

Rheumatologists provide the long-term care for 76% of ankylosing spondylitis patients. The late development of radiographic sacroiliitis and physicians' confusion of the disease with non-specific back pain contribute to a time to diagnosis of more than 3 years. Increased use of MRI will improve diagnosis rates and speed time to therapy initiation.

Reasons to Purchase

*Gain competitive advantage with one of the most extensive primary research reports available in psoriatic arthritis and ankylosing spondylitis

*Identify with prescribers more effectively, through an understanding of referral patterns based on data-rich treatment algorithms

*Validate new product forecasting based on diagnosis rates and treatment by patient segmentation and drug class

23-Dec-08 PDF & SlidePack Pges 195

Table of Contents
Price: $15,200.00 / €10,159.68

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions